Multivariate analysis revealed that high H19 expression might act as an independent prognostic biomarker for poor OS in non-APL-AML patients (HR = 1.554, P = 0.063, Table 3) but not whole-cohort AML (HR = 1.355, P = 0.169) or CN-AML patients (HR = 1.393, P = 0.313). The gene discussed is H19; the disease is acute myeloid leukemia.